Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
Status:
Completed
Trial end date:
2017-03-08
Target enrollment:
Participant gender:
Summary
A proof-of-concept for safety and preliminary clinical efficacy of a combined regimen of
INGAP-P for β-cell regeneration and ustekinumab for IL-12-23 autoimmune modulation in
patients with established T1DM.